FDA Approves New Therapy for Moderate to Severe Plaque Psoriasis
April 24th 2019In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).
Read More
New Federal Primary Care Payment Models: Another Step Toward Value Based Care
April 22nd 2019The Center for Medicare and Medicaid Innovation (CMMI) will be inviting primary care practices to participate in 5 new alternative payment models that will allow primary care practices to provide new types of services to their patients that are not supported by current Medicare payments.
Read More
FDA Approves Pembrolizumab Combo Therapy for Advanced Renal Cell Carcinoma
April 22nd 2019Pembrolizumab (Keytruda, Merck) has received FDA approval as a first-line treatment in combination with axitinib (Inlyta) for patients with advanced renal cell carcinoma (RCC), making it the first indication for pembrolizumab in this patient population.
Read More
Study Shows Precancerous Cervical Lesions Have Declined
April 22nd 2019Precancerous cervical lesions, known as high-grade cervical lesions (CIN2+) can develop a few years after infection and have been used to monitor human papillomavirus (HPV) vaccine impact since cancers can take decades to develop.
Read More
Hormone Therapy Combination Now Available for Treating Hot Flashes in Menopausal Women
April 18th 2019The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.
Read More